Concierge gives you timely BUY and SELL alerts on ASX-listed stocks
Emerging Stocks Down Under 6 September 2022: Medlab Clinical (ASX:MDC)
Medlab Clinical: Too many downside risks
Medlab Clinical (ASX: MDC) is one of the most unique biotechs on the ASX. It is rare to have a company that
has advanced a treatment to Phase 3 and even more so for a company that has a cannabis-based treatment,
but Medlab has done this. Still, it has not eliminated all uncertainty surrounding itself, including funding and a
potential listing on NASDAQ.
Click here to read the previous edition of Emerging Stocks Down Under published 30 August 2022.